Research Article
The Effect of Multiple Glycemic Parameters on Mortality and Clinical Outcomes in Critically Ill Patients in Intensive Care Unit
Issue:
Volume 10, Issue 2, June 2025
Pages:
26-36
Received:
18 March 2025
Accepted:
31 March 2025
Published:
22 April 2025
DOI:
10.11648/j.ijde.20251002.11
Downloads:
Views:
Abstract: Background: Dysglycemia is frequently encountered in the ICU and it includes hyperglycemia, hypoglycemia and glycemic variability which are associated with increased rate of mortality and morbidity. Hyperglycemia is the most frequent among the components of dysglycemia and its prevalence is 40-90%. The prevalence and outcome of multiple glycemic parameters in the ICU has not been described in Ethiopia. Objectives: The aim of the study is to describe the effect of multiple glycemic parameters on intensive care unit mortality and clinical outcomes in selected tertiary hospitals. Methods: An institution based cross-sectional study was conducted by using systematic random sampling. Data was collected from patient cards and was entered using Epi Info 7.2. Data analysis was done using SPSS 27.0. Descriptive statistics was used to summarize the data. Associations between variables were measured with chi square and Mann Whitney U test. Multivariable logistic regression was used to identify predictors of mortality and test the association of multiple glycemic parameters and mortality. Odds ratios with 95% confidence intervals were calculated, and a p-value <0.05 was considered to declare significance Result: The study included 392 patient records, with a median age of 38 years [IQR 28 – 56]. About 53% of patients were females. The prevalence of hyperglycemia, hypoglycemia and high glycemic variability was 90.3%, 16.3% and 19.4% respectively. Hypoglycemia was significantly associated with mortality (AOR 2.98, p < .05). Patients with hyperglycemia and hypoglycemia had significantly longer lengths of stay and durations of mechanical ventilation. High glycemic variability was not significantly associated with mortality, length of stay or duration of mechanical ventilation. Conclusion: Dysglycemia is very prevalent among patients admitted in the ICU and hypoglycemia may be associated with ICU mortality and adverse clinical outcomes.
Abstract: Background: Dysglycemia is frequently encountered in the ICU and it includes hyperglycemia, hypoglycemia and glycemic variability which are associated with increased rate of mortality and morbidity. Hyperglycemia is the most frequent among the components of dysglycemia and its prevalence is 40-90%. The prevalence and outcome of multiple glycemic pa...
Show More
Research Article
Role of Tirzepatide in Obesity Management Among Women with Polycystic Ovary Syndrome
Issue:
Volume 10, Issue 2, June 2025
Pages:
37-44
Received:
18 March 2025
Accepted:
31 March 2025
Published:
28 April 2025
DOI:
10.11648/j.ijde.20251002.12
Downloads:
Views:
Abstract: Introduction: Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women, often associated with obesity, insulin resistance, and metabolic complications. Managing weight is crucial for improving PCOS symptoms and overall health. This study aimed to evaluate the effectiveness of Tirzepatide, a novel dual GIP/GLP-1 receptor agonist, in obesity management and symptom improvement among women with PCOS. Methods: This retrospective observational study was conducted in the Department of Cardiology, Uttara Adhunik Medical College Hospital, LabAid Cancer Hospital & Super Speciality Centre, LabAid Diagnostics Center, Uttara, Dhaka, Bangladesh, from July 2024 to February 2025. In this study, we included 56 women with polycystic ovary syndrome associated with obesity who were referred to a consultant gynecologist or cardiologist for menstrual problems, obesity, and hypertension. Result: In this study, we found that after treatment, there was a significant weight reduction of 9.54% (p = 0.0004), with BMI decreasing from 36.51 ± 6.14 to 32.49 ± 4.68 kg/m² (p = 0.0002). Glycemic control improved significantly, with fasting blood sugar dropping from 6.89 ± 0.78 mg/dl to 5.57 ± 0.42 mg/dl (p < 0.0001) and HbA1c decreased from 5.7 ± 0.6% to 4.9 ± 0.4% (p < 0.0001). PCOS symptoms showed remarkable improvement, with irregular menstrual cycles decreased from 85.7% to 32.1% (p < 0.0001), and ovarian cyst prevalence dropped from 89.3% to 41% (p < 0.0001). Insulin resistance improved significantly (80.4% to 50%, p = 0.0008). The most common side effects were heartburn (42.86%), nausea/vomiting (39.29%), and general weakness (33.93%). Conclusion: In this study, Tirzepatide showed promising results in managing obesity and improving metabolic outcomes in women with PCOS. Significant weight reduction, glycemic control, and symptom improvement were observed in our study patients. Our study suggests that Tirzepatide could be a valuable therapeutic option for obese women with PCOS.
Abstract: Introduction: Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women, often associated with obesity, insulin resistance, and metabolic complications. Managing weight is crucial for improving PCOS symptoms and overall health. This study aimed to evaluate the effectiveness of Tirzepatide, a novel dual GIP/GLP-1 receptor agonist, in ...
Show More
,
Amare Gulilat Mamo
